S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
OncLive® On Air
00:00
Lower immune toxicity with ADC+PD‑1
Heather McArthur highlights unexpectedly low rates of immune‑related adverse events in the SG+pembrolizumab arm.
Play episode from 13:21
Transcript
